This article needs additional citations for verification. (March 2013)
The ECA stack is a drug combination used in weight loss and as a stimulant. ECA is an initialism for ephedrine, caffeine, and aspirin, with variants of it including the EC stack, which removes the aspirin for those who can not tolerate it. Dietary supplements based on or including elements of ECA were popular through the 1990s and early 2000s, but the marketing of ephedra- or ephedrine-containing stimulant combinations for weight loss and bodybuilding is now restricted or illegal in the United States, Canada and Netherlands due to reports of heart attack, stroke, and death associated with these supplements.
Use as a supplement
While it was available as a supplement, ECA was marketed with claims that it would aid weight loss, improve athletic performance and increase energy. Placebo-controlled studies have consistently found ephedrine in combination with caffeine to be effective in promoting moderate fat loss in the already-obese. A meta-analysis combining results from all available studies estimated average weight loss of 1 kg/month more than placebo. There is insufficient evidence to support use of ephedra for athletic performance.
Natural supplements that contain ephedra (aka Ma Huang) as an ephedrine substitute have been linked to cases of heart attack, stroke, and death in healthy young adults even when taken at the labeled dosage. A 2003 meta-analysis of all available studies and case reports concluded that: "ephedrine- and ephedra-containing dietary supplements [...] have harms in terms of a 2- to 3-fold increase in psychiatric symptoms, autonomic symptoms, upper gastrointestinal symptoms, and heart palpitations. More serious adverse effects from ephedra use cannot be excluded at a rate less than 1.0 per thousand, and case reports raise the possibility that a causal relationship with serious adverse events may exist."
Due to deaths linked to ephedra-containing dietary supplements and the potential use of ephedrine as a precursor in illegal methamphetamine manufacture, many countries have taken steps to regulate these products.
Status in The United States
In the United States, it is illegal to market products containing ephedrine or ephedra alkaloids as a dietary supplement. In 2004, ephedra, a botanical source of ephedrine alkaloids, was banned by the U.S. Food and Drug Administration due to serious safety concerns, injuries, and deaths linked to ephedra-containing supplements. However, ephedrine itself has never been illegal in the United States and is currently available over-the-counter. Reporting requirements and quantity limitations vary by state.
A Congressional report said that when an ephedra supplement company, Metabolife, in the USA was forced to release adverse event reports, cardiac and psychological reports were recorded in healthy young people at normal dosages.
Status in Canada
In January 2002, Health Canada issued a voluntary recall of all ephedrine products containing more than 8 mg per dose, all combinations of ephedrine with other stimulants such as caffeine, and all ephedrine products marketed for weight-loss or bodybuilding indications, citing a serious risk to health.
Status in Denmark
An EC formulation called Letigen which combined 20 mg of synthetic ephedrine and 200 mg of caffeine (recommended dose: 1-3 pills per day depending on user tolerance) was approved for sale by prescription in Denmark in 1990. During the peak of its use (in 1999) roughly 2% of the Danish population was using it. That product's marketing was discontinued in 2002 upon the same sort of adverse reports seen in other countries.
- "Dietary Supplements Containing Ephedrine Alkaloids". U.S. Food and Drug Administration. August 22, 2006. Retrieved July 7, 2009.
- "Health Canada requests recall of certain products containing Ephedra/ephedrine". Health Canada. January 9, 2002. Archived from the original on February 6, 2007. Retrieved July 7, 2009.
- Daly, P. A.; Krieger, D. R.; Dulloo, A. G.; Young, J. B.; Landsberg, L. (1993). "Ephedrine, caffeine and aspirin: Safety and efficacy for treatment of human obesity". International Journal of Obesity and Related Metabolic Disorders. 17 Suppl 1: S73–8. PMID 8384187.
- Shekelle, Paul G.; Hardy, Mary L.; Morton, Sally C.; Maglione, Margaret; Mojica, Walter A.; Suttorp, Marika J.; Rhodes, Shannon L.; Jungvig, Lara; Gagné, James (2003). "Efficacy and Safety of Ephedra and Ephedrine for Weight Loss and Athletic Performance". JAMA. 289 (12): 1537–45. doi:10.1001/jama.289.12.1470. PMID 12672771.
- Haller, Christine A.; Benowitz, Neal L. (2000). "Adverse Cardiovascular and Central Nervous System Events Associated with Dietary Supplements Containing Ephedra Alkaloids". New England Journal of Medicine. 343 (25): 1833–1838. doi:10.1056/NEJM200012213432502. PMID 11117974.
- "Erowid Ephedrine Vault : Legal Status".
- Minority Staff Report, Special Investigations Division "Adverse Event Reports from Metabolife"
- Hallas, J.; Bjerrum, L.; Stovring, H.; Andersen, M. (2008). "Use of a Prescribed Ephedrine/Caffeine Combination and the Risk of Serious Cardiovascular Events: A Registry-based Case-Crossover Study". American Journal of Epidemiology. 168 (8): 966–973. doi:10.1093/aje/kwn191. PMC 2565736. PMID 18756018.